Main > > >SARCOMA. *

---

DermatoFibroSarcoma Protuberans. TREAT.:
Imatinib Mesylate Tablets. Brand.
USA Approval Date: 2006. 11.01.
(*) Company : Novartis.
Patent : Expired.
TradeMark: Gleevec.
Web-Site : www.us.gleevec.com
UpDate: 2018. 12.17.




DermatoFibroSarcoma Protuberans. TREAT.:
Imatinib Mesylate Tablets. Generic.
USA Launch Date: 2016. 08.05.
(*) Company: Apotex.
UpDate: 2018. 12.17.




DermatoFibroSarcoma Protuberans. TREAT.:
Imatinib Mesylate Tablets. Generic.
USA Launch Date: 2017. 09.29.
(*) Company: Mylan.
UpDate: 2018. 12.17.




DermatoFibroSarcoma Protuberans. TREAT.:
Imatinib Mesylate Tablets. Generic.
USA Approval Date: 2016. 02.01.
(*) Company: Sun Pharma.
UpDate: 2018. 12.17.




Epithelioid Sarcoma. Treat.: Tazemeto- stat Tablets.
Histone MethylTransferase EZH2 Inhibitor
USA Approval Date: 2020. 01.23.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 02.06.




Kaposi s Sarcoma. AIDS Related. TREAT.:
Doxorubicin.HCl Liposome Inj. Brand
USA Initial Approval Year: 1995.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 12.16.




Kaposi Sarcoma. AIDS Related. TREAT.:
Doxorubicin.HCl Liposome Inj. Generic.
USA Approval Date: 2017. 05.17.
(*) Company: Dr. Reddy s Laboratories.
UpDate: 2018. 12.16.




Kaposi Sarcoma. AIDS Related. TREAT.:
InterFeroN Alpha 2b ReCombinant.
(*) Company : Merck.
Patent : Expired.
TradeMark: Intron-A
UpDate: 2018. 12.16.




Kaposi Sarcoma. AIDS Related. TREAT.:
Pomalidomide Capsules.
USA Approval Date: 2020. 05.15.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 09.20.




Onco.>RadioTherapy>BrachyTherapy>Low Ra-
te Dose (LRD) BrachyTherapy.
>Indications Potential>
>atypical meningioma
>non-small-cell lung cancer
>ocular melanoma
>Indications Used>
>colorectal cancer
>gynecological cancer
>head and neck cancer
>pancreatic cancer
>soft tissue sarcomas
USA Approval Date: 2014. 08.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 11.25.




OsteoSarcoma. Treat.: Methotrexate. High
Dose. AntiDote: LevoLeucovorin+Na for Inj.
USA Approval Date: 2018. 10.23.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.28.




Soft Tissue Sarcoma. TREAT.: Eribulin
Mesylate Inj.
(METASTATIC)
>Received Prior Anthracycline Treat
>SubTypes>LeiomyoSarcoma
>LipoSArcoma
>UnResectable
EU Approval Date : 2016. 05.06.
JP Approval Date : 2016. 02.29.
PH Approval Date : 2016. 06.01.
USA Approval Date: 2016. 01.29.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 12.16.




Soft Tissue Sarcoma. TREAT.: HfO2 Nano-
Particle Aqueous Suspension. (RadioEn-
hancer)
(LOCALLY ADVANCED).
RadioEnhancer>designed for Onjection directly into a Tumor Prior to a patient s first standard RadioTherapy Treatment. When exposed to Ionizing Radiation, RadioEnhancer Amplifies the Localized, IntraTumor killing effect of that Radiation. The Dose of X-Ray delivered to the tumor is Magnified, whilst the dose passing through healthy tissues remains unchanged. RadioEnhancer requires a single administration and will fit into current worldwide standards of radiation care.
EU Approval Date: 2019. 04.04.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 01.02.




Soft Tissue Sarcoma. TREAT.: Trabectedin
(METASTATIC)
>Received Prior Anthracycline Treat
>SubTypes>LeiomyoSarcoma
>LipoSarcoma
>UnResectable.
EU Approval Year : 2007.
JP Approval Date : 2015. 09.28.
USA Approval Date: 2015. 10.23.
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2018. 12.16.


>SARCOMA. *'s products
This section has no products